Hormone Research in Paediatrics
Original Paper
Estrogen Prevents Senescence through Induction of WRN, Werner Syndrome ProteinLee S.-J.a · Lee S.-H.a · Ha N.-C.b · Park B.-J.aaDepartment of Molecular Biology, College of Natural Science, bCollege of Pharmacy, Pusan National University, Busan, Republic of Korea
Keywords: EstrogenWRNATRSenescence |
|
Horm Res Paediatr 2010;74:33–40
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Received: February 02, 2009
Accepted: September 24, 2009
Published online: April 15, 2010
Issue release date: July 2010
Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Abstract
Werner syndrome is a well-known human progeria. It has been revealed that loss of human WRN is a causal factor of this disease. Since pathological features of Werner syndrome resemble those of menopausal women and become apparent during puberty, we examined the effect of estrogen on WRN gene expression. Here, we reveal that WRN is induced by estrogen but not testosterone. Treatment with estrogen can induce WRN expression at the transcription and translation level in a human breast cell line. Forced expression of the estrogen receptor can restore the responsiveness of WRN to estrogen in a non-responsive cell line. Treatment with estrogen can block DNA damage-induced senescence. Moreover, WRN is suppressed by ATR that is activated by DNA damage, whereas WRN can be induced by ATR elimination. Our results suggest that WRN is essential for prevention of senescence. In addition, our results imply that the reduction of WRN in menopause could be an important factor for menopausal syndrome.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, Matthews S, Nakura J, Miki T, Ouais S, Martin GM, Mulligan J, Schellenberg GD: Positional cloning of the Werner’s syndrome gene. Science 1996;272:258–262.
- Martin GM: Genetic modulation of senescent phenotypes in Homo sapiens. Cell 2005;120:523–532.
- Kipling D, Davis T, Ostler EL, Faragher GR: What can progeroid syndromes tell us about human aging? Science 2004;305:1426–1431.
- Martin GM, Oshima J: Lessons from human progeroid syndromes. Nature 2000;408:263–266.
- Kudlow BA, Kennedy BK, Monnat RJ Jr: Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 2007;8:394–404.
- Crabbe L, Verdun RE, Haggblom CI, Karlseder J: Defective telomere lagging strand synthesis in cells lacking WRN helicase activity. Science 2004;306:1951–1953.
- Sornay-Rendu E, Garnero P, Munoz F, Duboeuf F, Delmas PD: Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY study. Bone 2003;33:159–166.
- Schneider JG, Tompkins C, Blumenthal RS, Mora S: The metabolic syndrome in women. Cardiol Rev 2006;14:286–291.
- Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448–1459.
- Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS: Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006;66:10613–10620.
- Park BJ, Kang JW, Lee SW, Choi SJ, Shin YK, Ahn AH, Choi YH, Choi D, Lee KS, Kim S: The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR. Cell 2005;120:209–221.
- Park BJ, Oh, YS, Park SY, Choi SJ, Rudolph C, Schlegelberger B, Kim S: AIMP3 haploinsufficiency disrupts oncogene-induced p53 activation and genomic stability. Cancer Res 2006;66:6913–6918.
- Lee SH, Lee SJ, Jung YS, Xu YB, Kang HS, Ha NC, Park BJ: Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 2009;11:22–31.
- Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM: Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 2007;21:3763–3770.
- Simoncini T, Fornari L, Mannella P, Varone G, Caruso A, Liao JK, Genazzani AR: Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 2002;67:935–939.
- Buzdar AU: Fulvestrant – a novel estrogen receptor antagonist for the treatment of advanced breast cancer. Drugs Today (Barc) 2008;44:679–692.
- Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621–630.
- Provost PR, Blomquist CH, Godin C, Huang XF, Flamand N, Luu-The V, Nadeau D, Tremblay Y: Androgen formation and metabolism in the pulmonary epithelial cell line A549:expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3. Endocrinology 2000;141:2786–2794.
- Chen AC, Guo X, Derguini F, Gudas LJ: Human breast cancer cells and normal mammary epithelial cells: retinol metabolism and growth inhibition by the retinol metabolite 4-oxoretinol. Cancer Res 1997;57:4642–4651.
- Vigneron A, Roninson IB, Gamelin E, Coqueret O: Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005;65:8927–8935.
- Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661–665.
- Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656–660.
- Toledo LI, Murga M, Gutierrez-Martinez P, Soria R, Fernandez-Capetillo O: ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev 2008;22:297–302.
- Panda S, Isbatan A, Adami GR: Modification of the ATM/ATR directed DNA damage response state with aging and long after hepatocyte senescence induction in vivo. Mech Ageing Dev 2008;129:332–340.
- Murata K, Hatamochi A, Shinkai H, Ishikawa Y, Kawaguchi N, Goto M: A case of Werner’s syndrome associated with osteosarcoma. J Dermatol 1999;26:682–686.
- Grandori C, Wu KJ, Fernandez P, Ngouenet C, Grim J, Clurman BE, Moser MJ, Oshima J, Russell DW, Swisshelm K, Frank S, Amati B, Dalla-Favera R, Monnat RJ Jr: Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 2003;17:1569–1574.
- Opresko PL, von Kobbe C, Laine JP, Harrigan J, Hickson ID, Bohr VA: Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J Biol Chem 2002;277:41110–41119.
- Orren DK: Werner syndrome: molecular insights into the relationships between defective DNA metabolism, genomic instability, cancer and aging. Front Biosci 2006;11:2657–2671.
Article / Publication Details
First-Page Preview
Received: February 02, 2009
Accepted: September 24, 2009
Published online: April 15, 2010
Issue release date: July 2010
Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 0
ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)
For additional information: https://www.karger.com/HRP
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
